Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026 to help laboratories address workforce and workflow challenges
Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026 to help laboratories address workforce and workflow challenges |
| [22-July-2026] |
INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- (SIX: RO, ROP; OTCQX: RHHBY) As clinical laboratories face ongoing staffing shortages and increasingly complex workflows, Roche will showcase integrated diagnostic solutions designed to expand access to high-precision testing, automate laboratory workflows and improve operational efficiency at the Association for Diagnostics & Laboratory Medicine (ADLM) Annual Scientific Meeting & Clinical Lab Expo, July 28-30 in Anaheim, Calif.
Booth no. 2901 will feature the new AXELIOS 1 next-generation sequencing platform* and, for the first time, a live, in-booth unveiling of the cobas® Mass Spec solution at 10:15 a.m. PT, Tuesday, July 28, offering attendees an exclusive look at Roche's approach to automated clinical mass spectrometry. "The adversities we face extend far beyond individual laboratories: they span our entire healthcare ecosystem. Overcoming these systemic challenges requires more than standalone technologies; it demands connected solutions that drive radical efficiencies and swiftly bring high-medical-value diagnostics directly to the patients who need them most," said Antonio Vergara, Chief Commercial Officer of Roche Diagnostics U.S. "Our ADLM 2026 theme, Transforming Healthcare, Together, reflects our commitment to partnering with laboratory leaders at every step of their journey. Through automation, integrated solutions and award-winning service, we're helping laboratories improve efficiency while supporting confident clinical decisions." Visitors can explore interactive demonstrations focused on neurology, oncology and cardiometabolic health, highlighting innovations across core, molecular and pathology labs and point-of-care settings. Expanding access to high-precision science through mass spec automation The cobas® Mass Spec solution, which includes the cobas® i 601 analyzer and Ionify® reagents with CLIA "moderate complexity" classification, is designed to bring highly complex testing out of specialized units and into routine clinical core laboratories. From sample preparation to final result interpretation, this solution integrates end-to-end processing and eliminates labor-intensive manual workflows, helping laboratory professionals focus on higher-value work. Featured automation and analytical units in the Core Lab space include:
Redefining genomic discovery with next-generation sequencing by expansion (SBX) The AXELIOS 1 next-generation sequencing (NGS) platform*, powered by sequencing by expansion (SBX) technology, is designed to make genomics research faster, more flexible and more affordable for laboratories of all sizes. By reducing sequencing time from days to hours, it's designed to accelerate scientific discovery. Additional molecular platforms featured at the booth include:
AI and automation: Addressing pathology labor shortages Through expanded information solutions and deep software integrations, Roche is demonstrating how intelligent automation, cloud-based workflow visibility and AI-enabled diagnostics can reduce manual touchpoints and alleviate labor shortages. Together, Roche's staining and digital pathology solutions create a unified workflow that streamlines diagnostics. Featured systems include:
Expanding access to point-of-care solutions Highlighting decentralized testing, Roche is demonstrating a robust point-of-care ecosystem designed to facilitate rapid triage and improve operational efficiency, featuring:
Neurology and Alzheimer's disease breakthroughs Building on recent FDA clearances, Roche is spotlighting its Elecsys® Phospho-Tau (181P) blood-based biomarker test. As the only blood test FDA-cleared for use across primary-care settings to aid in ruling out Alzheimer's disease–associated amyloid pathology in adult patients aged 55 and older, presenting with signs and symptoms of cognitive decline, it represents an important advancement in expanding access to earlier clinical insight and risk assessment. navify® Digital Solutions: Turning data into actionable insights Centralized interactive stations across the booth will showcase the navify® Digital Solutions portfolio, including navify Lab Operations, navify Analytics, navify Quality Suite, and navify POC Operations. These systems turn complex lab data into actionable insights by providing proactive issue detection, workload prediction, and comprehensive operational visibility across core lab and point-of-care settings. Learn more about Roche at ADLM 2026 by visiting ADLM.Roche.com. *The AXELIOS 1 Sequencing Platform is available for Research Use Only. Not for use in diagnostic procedures. About Roche Roche was founded in Basel, Switzerland, in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. Media Inquiries Roche Diagnostics U.S. Media Relations Jen Dial Amy Lynn
SOURCE Roche | ||
Company Codes: OTC-BB:RHHBY,OTC-QX:RHHBY,Swiss:RO,Swiss:ROP |
View original content to download multimedia:
